Venturing into the unknown – Express Pharma
Less VC, more PE
The recent years have witnessed a decrease in Venture Capital (VC) funding in the pharma and biotech space and an increase in Private Equity (PE). PE is the capital acquired by a company to fund its expansion activities when a company reaches the growth stage. Timmy Kandhari, Executive Director, PriceWaterhouseCoopers, opines that 2005 has been a good year for the country with foreign institutional investments crossing the $10 billion mark and amounts raised through IPOs aggregating to $6 billion.